1.中山大学附属第三医院感染科,广东 广州 510630
2.中山大学附属第三医院输血科,广东 广州 510630
3.广东轻工职业技术学院,广东 广州 510300
陈晓彤,医学硕士,研究方向:慢性乙型肝炎,E-mail: chenxt37@mail2.sysu.edu.cn
收稿:2021-07-22,
纸质出版:2022-01-20
移动端阅览
陈晓彤,梁静,刘相富等.慢性乙型肝炎患者外周单核细胞衍生的巨噬细胞的极化状态与HBV DNA的相关性及其动态变化[J].中山大学学报(医学科学版),2022,43(01):86-95.
CHEN Xiao-tong,LIANG Jing,LIU Xiang-fu,et al.Correlation and Dynamic Changes between the Polarization of Monocyte-derived Macrophages and HBV DNA in Chronic Hepatitis B[J].Journal of Sun Yat-sen University(Medical Sciences),2022,43(01):86-95.
陈晓彤,梁静,刘相富等.慢性乙型肝炎患者外周单核细胞衍生的巨噬细胞的极化状态与HBV DNA的相关性及其动态变化[J].中山大学学报(医学科学版),2022,43(01):86-95. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2022.0111.
CHEN Xiao-tong,LIANG Jing,LIU Xiang-fu,et al.Correlation and Dynamic Changes between the Polarization of Monocyte-derived Macrophages and HBV DNA in Chronic Hepatitis B[J].Journal of Sun Yat-sen University(Medical Sciences),2022,43(01):86-95. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2022.0111.
目的
2
为了研究慢性乙型肝炎(CHB)患者在核苷(酸)类(恩替卡韦(ETV)或替诺福韦(TDF))抗病毒治疗过程中外周单核细胞衍生的巨噬细胞 (MDMs) 的极化化状态的动态变化以及与HBV DNA、HBeAg的相关性。
方法
2
共纳入101例CHB患者和20名健康人的外周血标本。通过外周血单核细胞技术(PBMC)分离培养获得86例CHB患者和12例健康人的MDMs。采用流式细胞技术检测MDMs的特异性标志物(CD80,HLA-DR,CD163和CD206)的表达,从而评估MDMs的极化状态(即M1型/M2型极化状态)。通过qPCR检测15例CHB患者和8例健康对照中MDMs的炎症因子的mRNA水平表达。
结果
2
我们发现在CHB患者外周血中CD163
+
CD206
+
MDMs(M2型MDMs)的比例较正常人群显著减少(
P
= 0.030)。同时,抑炎因子IL-10的mRNA水平表达也明显下降(
P
= 0.040)。随着核苷(酸)类似物抗病毒治疗的进展,CD163
+
CD206
+
MDMs(M2型)的比例逐渐增加(
P
<
0.001),而CD80
+
HLA-DR
+
MDMs(M1型)逐渐地降低(
P
= 0.005)。另外,M2型MDMs与HBeAg(
P
= 0.019),HBV DNA水平(
P
= 0.002),AST(
P
= 0.048)和ALT(
P
= 0.030)均呈负相关。ROC曲线分析表明M2型MDMs对CHB抗病毒治疗的病毒学应答率有一定的预测作用,可预测HBV DNA阴转率[ROC
95%CI为0.705(0.594,0.815)]和HBeAg的血清转化率[ROC
95%CI为0.740(0.634,0.847)]。
结论
2
CHB患者在核苷(酸)类抗病毒治疗过程中MDMs极化状态呈现规律动态变化,M2型MDMs与HBV DNA和HBeAg水平呈负相关,对CHB抗病毒治疗的病毒学应答率有一定预测作用。
Objective
2
To investigate the dynamic change of monocyte-derived macrophages (MDMs) in chronic hepatitis B (CHB) during the treatment by ETV or TDF, and the association between the polarization of monocyte-derived macrophages (MDMs) and HBV DNA, HBeAg in CHB.
Methods
2
Peripheral blood of 101 patients with chronic hepatitis B and 20 healthy donors were enrolled. MDMs were purified from 86 patients with CHB and 12 healthy donors by peripheral blood mononuclear cell (PBMC). Flow cytometry was use to analyze the expression of specific markers on polarized macrophages to further evaluate the polarization of MDMs (M1/M2 MDMs), including CD80, HLA-DR, CD163 and CD206. Additionally, qPCR was used to evaluate the mRNA expression of inflammatory factors of MDMs in 15 patients with chronic hepatitis B and 8 healthy controls.
Results
2
The proportion of CD163
+
CD206
+
MDMs (M2 MDMs) were reduced in patients with CHB (
P
= 0.030), compared with healthy controls. Correspondingly, the mRNA expression of anti-inflammatory factor, IL-10, decreased significantly (
P
= 0.040). With the progress of nucleos(t)ide analogs (NAs) therapy, the proportion of CD163
+
CD206
+
MDMs (M2 MDMs) increased gradually (
P
<
0.001), while the proportion of CD80
+
HLA-DR
+
MDMs (M1 MDMs) decreased gradually (
P
= 0.005). In addition, M2 MDMs were negatively associated with both HBeAg (
P
= 0.019), HBV DNA (
P
= 0.002), AST (
P
= 0.048) and ALT (
P
= 0.030) in patients with CHB. ROC curve analysis showed that CD163
+
CD206
+
MDMs (M2 MDMs) had high predicting value for the virologic response of CHB during NA therapy, and could be used to predict undetectable HBV DNA [ROC 95%CI: 0.705 (0.594,0.815)] and HBeAg seroconversion [ROC 95%CI: 0.740 (0.634,0.847)].
Conclusions
2
There are dynamic changes of MDMs polarization in patients with CHB during NA therapy, and the negative correlation between the proportion of M2 MDMs and HBV DNA, HBeAg indicates that M2 MDMs could have a high predicting value in the virologic response of CHB during NA therapy.
Dandri M , Locarnini S . New insight in the pathobiology of hepatitis B virus infection [J]. Gut , 2012 , 61 Suppl 1 : i6 - 17 .
Seeger C , Mason WS . Molecular biology of hepatitis B virus infection [J]. Virology , 2015 , 479-480 : 672 - 86 .
Wu YL , Shen CL , Chen XY . Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis [J]. World J Clin Cases , 2019 , 7 ( 14 ): 1784 - 1794 .
Yim HJ , Kim JH , Park JY , et al . Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop [J]. Clin Mol Hepatol , 2020 , 26 ( 4 ): 411 - 429 .
Pol S , Lampertico P . First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice [J]. J Viral Hepat , 2012 , 19 ( 6 ): 377 - 386 .
Han SH , Tran TT . Management of chronic hepatitis B: an Overview of Practice Guidelines for Primary Care Providers [J]. J Am Board Fam Med , 2015 , 28 ( 6 ): 822 - 837 .
Ke W , Liu L , Zhang C , et al . Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis [J]. PLoS One , 2014 , 9 ( 6 ): e98865 .
Trombetta AC , Soldano S , Contini P , et al . A circulating cell population showing both M1 and M2 monocyte/macrophage surface markers characterizes systemic sclerosis patients with lung involvement [J]. Respir Res , 2018 , 19 ( 1 ): 186 .
Mily A , Kalsum S , Loreti MG , et al . Polarization of M1 and M2 human monocyte-derived cells and analysis with flow cytometry upon mycobacterium tuberculosis infection [J]. J Vis Exp , 2020 , ( 163 ): 10.3791/61807 .
Shapouri-Moghaddam A , Mohammadian S , Vazini H , et al . Macrophage plasticity, polarization, and function in health and disease [J]. J Cell Physiol , 2018 , 233 ( 9 ): 6425 - 6440 .
Davies LC , Jenkins SJ , Allen JE , Taylor PR . Tissue-resident macrophages [J]. Nat Immunol , 2013 , 14 ( 10 ): 986 - 995 .
Li TY , Yang Y , Zhou G , Tu ZK . Immune suppression in chronic hepatitis B infection associated liver disease: a review [J]. World J Gastroenterol , 2019 , 25 ( 27 ): 3527 - 3537 .
王贵强 , 王福生 , 成军 , 等 . 慢性乙型肝炎防治指南(2015年版) [J]. 实用肝脏病杂志 , 2016 , 19 ( 3 ): 389 - 400 .
Wang GQ , Wang FS , Cheng J , et al . The guideline of prevention and treatment for chronic hepatitis B: a 2015 update [J]. J Clin Hepat , 2016 , 19 ( 3 ): 389 - 400 .
Zarif JC , Hernandez JR , Verdone JE , et al . A phased strategy to differentiate human CD14+monocytes into classically and alternatively activated macrophages and dendritic cells [J]. Biotechniques , 2016 , 61 ( 1 ): 33 - 41 .
Yi H , Zhang Y , Yang X , et al . Hepatitis B core antigen impairs the polarization while promoting the production of inflammatory cytokines of M2 macrophages via the TLR2 pathway [J]. Front Immunol , 2020 , 11 : 535 .
Zhang Q , Wang Y , Zhai N , et al . HCV core protein inhibits polarization and activity of both M1 and M2 macrophages through the TLR2 signaling pathway [J]. Sci Rep , 2016 , 6 : 36160 .
Wu J , Han M , Li J , et al . Immunopathogenesis of HBV Infection [J]. Adv Exp Med Biol , 2020 , 1179 : 71 - 107 .
Laursen TL , Wong GL , Kazankov K , et al . Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment [J]. J Gastroenterol Hepatol , 2018 , 33 ( 2 ): 484 - 491 .
Tacke F , Zimmermann HW . Macrophage heterogeneity in liver injury and fibrosis [J]. J Hepatol , 2014 , 60 ( 5 ): 1090 - 1096 .
Gantzel RH , Kjær MB , Laursen TL , et al . Macrophage activation markers, soluble CD163 and mannose receptor, in liver fibrosis [J]. Front Med (Lausanne) , 2021 , 7 : 615599 .
Kazankov K , Barrera F , Møller HJ , et al . Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C [J]. Hepatology , 2014 , 60 ( 2 ): 521 - 530 .
Waidmann O , Brunner F , Herrmann E , et al . Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis [J]. J Hepatol , 2013 , 58 ( 5 ): 956 - 961 .
Rainer F , Horvath A , Sandahl TD , et al . Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation [J]. Aliment Pharmacol Ther , 2018 , 47 ( 5 ): 657 - 664 .
Kazankov K , Rode A , Simonsen K , et al . Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma [J]. Scand J Clin Lab Invest , 2016 , 76 ( 1 ): 64 - 73 .
0
浏览量
345
下载量
1
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621
